Objective: To explore the efficacy of atorvastatin combined with alirocumab in the treatment of patients with coronary heart disease and hyperlipidemia. Methods: The study period was from June 2024 to June 2025. Patients with coronary heart disease and hyperlipidemia (n = 506) who received diagnosis and treatment in our hospital during this time period were included as the study subjects. The observation group and the control group were divided based on a random number table, with 253 patients in each group. Clinical treatment indicators were compared between the groups. Results: The total effective rate in the observation group was higher than that in the control group (P < 0.05). After treatment, there were significant differences in blood lipid levels, cardiac function indicators, coronary microcirculation, and inflammatory factor levels between the groups (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion: The combination of atorvastatin and alirocumab in the treatment of patients with coronary heart disease and hyperlipidemia is not only beneficial for improving cardiac function and blood lipid symptoms, but also has a prominent effect on coronary microcirculation and anti-inflammatory ability. The treatment is effective and safe, and can be promoted.
No takes yet. Share an insight, caveat, or question.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: